Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 185.97

-0.4%

Feb 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: squetch who wrote (7317)	9/23/1997 5:42:00 PM
From: Henry Niman	of 32384

Stan, I supose generic is as good of a description as any other. If a drug is off patent, companies can use orphan drug status to protect their discovery or development of such a drug for a new indication (provided that the new indication is small enough of a market to fall under the orphan drug act). The provision is to encourage development of a drug in a small market. Thus if Taxol is developed for a given indication, someone else would be barred from using the same drug for the same indication. If Paxene is essentially the same as Paxlitaxel (two brand names for Taxol?) and one has been approved for KS (and granted orphan drug status), I think that there is a seven year problem for the other one.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next